WAT

Business profile & competitive position

Waters Corporation sits in the Healthcare sector, under the Medical – Diagnostics & Research industry. It designs, manufactures, sells and services analytical technologies: high-performance and ultra-performance liquid chromatography (LC), mass spectrometry (MS), thermal analysis, rheometry and calorimetry (TA) instruments, plus the consumables, software and service plans that keep those instruments running. Its products are used in pharmaceutical, clinical, biochemical, industrial, nutritional-safety, environmental, academic and government laboratories, frequently as integrated LC-MS systems operating on common software platforms. Following the February 2026 acquisition of BD's Biosciences and Diagnostic Solutions businesses, Waters also offers diagnostics specimen collection, infectious-disease and cancer testing systems, flow cytometry, and multiomics tools.

The margin and return metrics in the current snapshot raise questions about how wide the moat looks today. Net margin is 3.6% and ROE is just 1.9%, levels that are unusually low for a company with a large installed base of precision instruments. In analytical instrumentation, competitive advantage typically comes from customer lock-in through proprietary methods, software workflows, regulatory-validated systems and high-margin recurring service revenue. Waters does show that recurring element: service revenue represented more than 35% of Waters' 2025 sales and more than 25% of TA's 2025 sales. Yet the 3.6% net margin and 1.9% ROE suggest that near-term integration costs and the scale of the BD combination are overwhelming the underlying instrument economics for now. The moat may be intact at the product level, but it is not translating into strong reported returns on equity at this stage.

Financial posture

Waters currently trades at $410.75 with a market capitalization of $30.7 billion. The valuation multiple stands at a P/E of 102.2, supported by a net margin of 3.6% and an ROE of 1.9%. The stock's beta is 1.18, which implies slightly more volatility than the overall market. On the technical snapshot, RSI is 59.4 and the 50-day EMA is $384.79, so price is trading roughly $26 above that moving average.

A P/E above 100 is difficult to justify from current profitability alone. With net margin at 3.6% and ROE at 1.9%, the market is clearly pricing in a meaningful transformation rather than the current earnings power of the legacy Waters business. The $30.7 billion market cap also sits in the shadow of the $16.8 billion purchase price Waters paid for BD's Biosciences and Diagnostic Solutions businesses, including assumed debt. That acquisition price represents more than half of the current equity value, underscoring that the combined company's valuation is now heavily tied to how successfully Waters integrates and extracts value from BD's diagnostics and life-sciences assets.

Strategic priorities & outlook

Waters' most recent SEC 10-K filing frames the company as a work in progress. The first priority is reorganizing the combined company into four segments: Waters Analytical Sciences, Waters Biosciences, Waters Advanced Diagnostics, and Waters Materials Sciences. Management states it will evaluate the newly organized business activities to determine operating and reporting segments for future reporting periods, so investors should expect segment disclosures to evolve as the integration matures.

The filing also emphasizes continued significant R&D investment to develop new products and enhance existing LC, MS, TA and diagnostics offerings. In parallel, Waters intends to pursue additional outsourcing opportunities while maintaining adequate internal supply chain and manufacturing capabilities. The BD Biosciences and Diagnostic Solutions acquisition closed on February 9, 2026, for a total purchase price of $16.8 billion including assumed debt. It was structured as a Reverse Morris Trust, leaving BD shareholders with approximately 39.2% of the combined company. That ownership overhang is a material feature of the equity story.

On the revenue base, the 2025 mix before the BD deal was 59% to pharmaceutical accounts, 30% to other industrial accounts, and 11% to academic and government agencies. No single customer accounted for more than 2% of net sales, which limits customer concentration risk even though sector concentration to pharma is high.

Macro & geopolitical exposure

As a Healthcare/Medical – Diagnostics & Research business, Waters carries the macro sensitivities typical of regulated life-sciences and diagnostic equipment companies. Regulatory risk is structurally high: instruments and diagnostics used in clinical, pharmaceutical and food-safety workflows must satisfy FDA, EU MDR, and other regional standards, and any delay in approvals or changes to diagnostic reimbursement rules can affect demand. With 59% of pre-acquisition sales going to pharmaceutical accounts, the company is also exposed to biopharma R&D spending cycles and capital-allocation decisions at large drugmakers.

Trade policy matters here because analytical instruments and their consumables are manufactured and sold globally; tariffs or export restrictions on precision components can move gross margins and delivery timelines. Currency risk is present as well, since a meaningful portion of revenue is generated outside the United States. The 11% exposure to academic and government agencies makes the company sensitive to public science budgets, such as NIH or NSF funding levels. Finally, commodity and logistics costs for specialty metals, chemicals and electronics used in instruments and consumables can pressure manufacturing economics.

Recent developments

The most recent headline, dated August 23, 2026, from seekingalpha.com, noted Invesco Discovery Mid Cap Growth Fund's Q2 2026 portfolio performance, placing Waters within a growth-focused fund context. On August 15, 2026, defenseworld.net reported that Assetmark Inc. holds a $1.57 million stake in Waters Corporation. That same source reported on August 10, 2026, that Dudley & Shanley Inc. holds an $8.85 million stake. Also on August 10, 2026, defenseworld.net reported that a Waters director sold $1,442,930.44 in stock.

Read together, the flow suggests mixed institutional signals: registered investment advisors were accumulating or holding positions in the first half of August, while an insider was reducing exposure. The director sale stands out because it occurred on the same day as one of the institutional-stake disclosures. None of these filings alone explains a change in fundamentals, but they do illustrate that market participants are repositioning around the post-BD Waters story as the integration unfolds.

Earnings behavior & post-earnings drift

Waters has beaten earnings estimates in all eight of the most recent reported quarters, for a beat rate of 8/8 (100%). The average earnings surprise across those quarters was 4.7%. The average 5-day price move in the trading days following earnings was 2.67%, classified as an upward drift. That pattern suggests the market has consistently underpriced the company's near-term earnings power, and that positive surprises have generally been absorbed into the stock price over the following week rather than fully repriced overnight.

The last four quarters show the beat streak is broad but uneven in magnitude. On August 4, 2026, Waters reported actual EPS of $3.05 versus an estimate of $3.01, a 1.3% surprise; the stock rose 0.99% the next day and 4.78% over the following five days. On May 5, 2026, actual EPS was $2.70 versus $2.31, a 16.9% surprise; the stock moved up 2.04% the next day and 2.83% over five days. On February 9, 2026, actual EPS of $4.53 beat the $4.51 estimate by only 0.4%, and the stock slipped 0.34% the next day and 2.04% over five days. On November 4, 2025, actual EPS of $3.40 beat the $3.21 estimate by 5.9%, driving a 1.26% next-day gain and a 5.12% five-day gain.

The next scheduled earnings release is November 3, 2026, before the open, with a current consensus EPS estimate of $4.01. The historical record says Waters has beaten the official consensus every time over the past two years, but the post-ear reaction has varied: the smallest surprise produced the weakest five-day return, while the largest surprises produced strong but not explosive follow-through. For traders and analysts, the real question around the November 3 report is not simply whether Waters beats, but whether the market's real expectation and the quality of the BD-integration commentary are already priced into a stock trading near $411 with a triple-digit P/E.

For a deeper dive into how institutional analysts are weighing Waters' integration execution, valuation premium, and the November 2026 earnings setup, consider reviewing the full institutional verdict on the ticker page.